What's going on with the Inoviq (ASX:IIQ) share price today?

The company is set to finish the week on a high note.

| More on:
Female scientist working in laboratory for Race Oncology

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Inoviq Ltd (ASX: IIQ) share price is racing higher during early Friday afternoon. This comes after the medical diagnostics company announced it has secured a new patent for diagnosing lung cancer.

At the time of writing, Inoviq shares are up 4.21% to $1.115 apiece. In contrast, the All Ordinaries (ASX: XAO) is up 0.63% to 7,755.9 points.

Inoviq granted new patent protection

Investors are pushing Inoviq shares higher after digesting the company's positive update.

In its release, Inoviq advised that it has been granted a patent to add to its growing portfolio. Approved by the Chinese Patent Office, the latest addition will seek to further protect Inoviq's intellectual property.

Titled, 'Lung Cancer Diagnosis', the new patent explains the methods towards detecting antibodies to BARD1 peptides. This is for diagnosing lung cancer and developing an autoantibody test kit in the world's second biggest health care market.

The new patent is set to expire on 5 February 2035.

Inoviq CEO, Dr Leearne Hinch commented:

This patent enforces intellectual property protection in China for a potential BARD1-Lung cancer test that detects autoantibodies associated with lung cancer. Patent family PCT/EP2014/073834 now has seven granted patents in Australia, China, Israel, Japan, Korea, Singapore and the USA.

Quick take on Inoviq

Formerly known as BARD1 Life Sciences, Inoviq is an Australian-based medical diagnostics company that is focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer.

The company's proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes two development-stage autoantibody tests for early detection of lung and ovarian cancers.

Inoviq is headquartered in Perth, Australia, and has contract research laboratories at the University of Geneva, Switzerland.

Inoviq share price summary

In the past 12 months, Inoviq shares have accelerated to more than 60%. However, year-to-date performance has further jumped to post a gain above 66%.

Based on valuation metrics, Inoviq presides a market capitalisation of roughly $102.60 million, with approximately 92.02 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »

A woman puts up her hands and looks confused while sitting at her computer.
Healthcare Shares

Down 5%: What's going on with the ResMed share price?

Let's see what has spooked investors today and caused them to push the sell button.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »